A NEW artificial intelligence (AI) drug discovery platform has been launched to help accelerate the development of treatments for major global diseases, with free access provided to eligible researchers worldwide.
The platform, known as dd4gh (Drug Design for Global Health), was developed by Medicines for Malaria Venture and deepmirror to address persistent barriers in drug development, particularly in low- and middle-income countries.
AI Drug Discovery Platform Expands Access
The AI drug discovery platform is designed to support scientists working on diseases such as malaria, tuberculosis, and neglected tropical diseases. These conditions disproportionately affect populations in resource-limited settings, where access to advanced research tools is often restricted.
By offering the platform free of charge, the initiative aims to democratise access to cutting-edge AI technologies that would otherwise be too costly for many researchers.
AI Drug Discovery Platform Uses Advanced AI Models
The platform integrates both predictive and generative AI, enabling researchers to analyse large datasets and identify promising drug candidates more efficiently. It also incorporates active learning, allowing the system to continuously refine its predictions based on new data.
This approach helps prioritise compounds with the highest likelihood of success, potentially reducing the time and cost associated with traditional drug discovery processes.
Co-Creation with Global Researchers
The AI drug discovery platform was developed through collaboration with global health researchers, including workshops held in Ghana and Switzerland. These efforts ensured the tool reflects the real-world needs of scientists working in high-burden settings.
By training its models on diverse datasets from global health studies, the platform enables users to benefit from insights generated across multiple research environments.
Driving Equity in Drug Development
Access to AI-driven drug discovery tools has traditionally been limited by cost and infrastructure. The launch of dd4gh seeks to address this imbalance by empowering researchers in underserved regions to lead innovation in diseases affecting their communities.
The AI drug discovery platform could significantly accelerate the development of new treatments by enabling faster identification of viable drug candidates and reducing reliance on resource-intensive laboratory work.
By widening access to advanced AI tools, the platform also supports a more inclusive global research ecosystem, where scientists in all regions can contribute to solving pressing health challenges.
As global health systems face increasing pressure, such innovations may play a critical role in speeding up the delivery of life-saving therapies to the populations that need them most.
Reference
Medicines for Malaria Venture (MMV). Free AI drug discovery platform aims to level the playing field for global health research. 31 March 2026. Available at: https://www.mmv.org/news-resources-search/free-ai-drug-discovery-platform-aims-level-playing-field-global-health. Last accessed: 02 April 2026.
Featured image: Nuttapong on Adobe Stock
